Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667446 · ClinicalTrials.gov registry record · Phase 3
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
A Phase 3 study of Precocious and Leuprolide Acetate, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT00667446 is a Phase 3 study of Precocious and Leuprolide Acetate that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 72 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT00667446, a Phase 3 study of Precocious and Leuprolide Acetate, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
Conditions Studied
Interventions
- DRUG Leuprolide Acetate 3 Month Depot
Study Locations (20)
Other
- Site Reference ID/Investigator# 23182 - Bayamón
- Site Reference ID/Investigator# 21721 - Ponce
- Site Reference ID/Investigator# 25908 - Rio Piedras
- Site Reference ID/Investigator# 23082 - San Juan
California
- Site Reference ID/Investigator# 14922 - Long Beach
- Site Reference ID/Investigator# 26043 - Los Angeles
- Site Reference ID/Investigator# 20802 - San Diego
Florida
- Site Reference ID/Investigator# 18181 - Jacksonville
- Site Reference ID/Investigator# 26364 - Pensacola
Minnesota
- Site Reference ID/Investigator# 23643 - Minneapolis
- Site Reference ID/Investigator# 23502 - Saint Paul
Oklahoma
- Site Reference ID/Investigator# 23802 - Oklahoma City
- Site Reference ID/Investigator# 13324 - Tulsa
Alabama
- Site Reference ID/Investigator# 13521 - Birmingham
Colorado
- Site Reference ID/Investigator# 22425 - Greenwood Village
Indiana
- Site Reference ID/Investigator# 26983 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667446
The ClinicalTrials.gov registry entry for NCT00667446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Precocious appearing as the primary indexed condition, and to 1 intervention - of which Leuprolide Acetate 3 Month Depot is the first listed.
NCT00667446 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00667446 about?
NCT00667446 is a clinical study titled "Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty". The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
What is the current status of trial NCT00667446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2008-12. Estimated completion is 2013-01.
What conditions does trial NCT00667446 study?
This clinical trial studies the following conditions: Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging.
What interventions are being tested in trial NCT00667446?
The interventions under investigation include: Leuprolide Acetate 3 Month Depot (DRUG).
Who is sponsoring clinical trial NCT00667446?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00667446 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.